Edition:
India

Celon Pharma SA (CLNP.WA)

CLNP.WA on Warsaw Stock Exchange

46.10PLN
7:38pm IST
Change (% chg)

-1.40zł (-2.95%)
Prev Close
47.50zł
Open
47.50zł
Day's High
47.95zł
Day's Low
46.10zł
Volume
7,953
Avg. Vol
15,504
52-wk High
51.10zł
52-wk Low
28.25zł

Latest Key Developments (Source: Significant Developments)

Celon Pharma Q1 Net Profit Down At 6.5 Mln Zlotys
Monday, 13 May 2019 

May 14 (Reuters) - CELON PHARMA SA ::REPORTED ON MONDAY Q1 NET PROFIT OF 6.5 MILLION ZLOTYS VERSUS 7.5 MILLION ZLOTYS YEAR AGO.Q1 REVENUE OF 27.1 MILLION ZLOTYS VERSUS 28.2 MILLION ZLOTYS YEAR AGO.Q1 OPERATING PROFIT OF 6.7 MILLION ZLOTYS VERSUS 8.1 MILLION ZLOTYS YEAR AGO.  Full Article

German Courts Prohibit Placing of Celon Pharma's Salmex On Market
Thursday, 25 Apr 2019 

April 25 (Reuters) - Celon Pharma SA ::DISTRIBUTION PARTNER GLENMARK ARZMEIMITTEL SAYS COURTS DECIDED TO GIVE GLAXOSMITHKLINE'S COMPANIES PROCEDURAL PROTECTION.SAYS PROCEDURAL PROTECTION INCLUDES PROHIBITION ON PLACING ON SWEDEN, DENMARK, GERMANY'S MARKET CO'S INHALER SALMEX.  Full Article

Celon Pharma FY Net Profit Up At 29.7 Mln Zlotys
Tuesday, 19 Mar 2019 

March 20(Reuters) - CELON PHARMA ::REPORTED ON TUESDAY NET PROFIT OF 29.7 MILLION ZLOTYS VERSUS 25.6 MILLION ZLOTYS YEAR AGO.FY REVENUE OF 125.2 MILLION ZLOTYS VS 107.1 MILLION ZLOTYS.FY OPERATING PROFIT OF 35.6 MILLION ZLOTYS VERSUS 26.0 MILLION ZLOTYS YEAR AGO.  Full Article

Celon Pharma Granted Patent In The US
Sunday, 27 Jan 2019 

Jan 28 (Reuters) - Celon Pharma SA ::SAID ON SUNDAY THAT IT HAS BEEN GRANTED PATENT FOR PDE10A INHIBITORS AND THEIR USE IN TREATMENT OF NEUROLOGICAL AND PSYCHOTIC DISEASES AND DISORDERS IN THE US.  Full Article

Celon Pharma Gets Patent For PI3K Inhibitors In U.S.
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - Celon Pharma SA ::SAID ON TUESDAY THAT IT RECEIVED PATENT IN U.S. FOR PI3K INHIBITORS, WHICH ARE USED IN TREATMENT OF IMMUNOLOGICAL DISEASES, INFLAMMATORY DISEASES AND IN ONCOLOGY THERAPIES .PATENT GUARANTEES FULL LEGAL PROTECTION IN THE UNITED STATES.PATENT PROTECTION INCREASES VALUE OF POTENTIAL COMMERCIALIZATION OF COMPANY'S PRODUCTS IN THERAPEUTIC AREAS COVERED BY PATENT PROTECTION.  Full Article

Celon Pharma Q3 Net Profit Rises To 8.3 Million Zlotys
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - CELON PHARMA SA ::Q3 REVENUE 31.7 MILLION ZLOTYS VERSUS 24.2 MILLION ZLOTYS YEAR AGO.Q3 NET PROFIT 8.3 MILLION ZLOTYS VERSUS 4.9 MILLION ZLOTYS YEAR AGO.Q3 OPERATING PROFIT 8.1 MILLION ZLOTYS VERSUS 4.2 MILLION ZLOTYS YEAR AGO.  Full Article

Celon Pharma FY Net Profit Down At 25.6 Million Zlotys
Tuesday, 17 Apr 2018 

April 17 (Reuters) - CELON PHARMA SA ::SAID ON MONDAY THAT ITS FY NET PROFIT WAS 25.6 MILLION ZLOTYS VERSUS 37.8 MILLION ZLOTYS YEAR AGO.FY REVENUE WAS 107.1 MILLION ZLOTYS VERSUS 128.8 MILLION ZLOTYS YEAR AGO.  Full Article

Celon Pharma Supervisory Board Chairman Resigns
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - CELON PHARMA SA ::MACIEJ ANDRZEJ KRASINSKI RESIGNS FROM HIS POST AS CHAIRMAN OF CO'S SUPERVISORY BOARD.  Full Article

Celon Pharma To Get PLN 24.7 Mln Financing For Development Of Biosimilar Drug
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - CELON PHARMA SA ::SIGNS AGREEMENT FOR FUNDING OF ITS PROJECT WITH NATIONAL CENTRE FOR RESEARCH AND DEVELOPMENT.UNDER AGREEMENT TO GET PLN 24.7 MILLION FINANCING FOR DEVELOPMENT OF BIOSIMILAR DRUG BASED ON FAB FRAGMENT.  Full Article

Celon Pharma Plans To Place Salmex On Scandinavian Markets In H1 2018
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - CELON PHARMA SA ::INFORMS THAT REGISTRATION PROCEDURE OF SALMEX DRUG IN SCANDINAVIAN COUNTRIES ENDS POSITIVELY.ESTIMATES THAT WILL PLACE SALMEX ON SCANDINAVIAN MARKETS IN H1 2018.  Full Article